Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,267.00+0.58%ETH$2,510.86+2.27%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
CR

NASDAQ · CRDL

Cardiol Therapeutics Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$2.00

Up+$0.02 (+0.76%)

Updated Sep 12, 2026, 5:09 AM

SID Score

5.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
94.81M
P/E ratio
-3.26
Dividend yield
0.00%
52-week range
$0.90 – $2.34
Volume
1.24M
Avg. volume
704.06K

Price performance

CRDL price history

1M range · 20 trading sessions · Daily adjusted prices

CRDL closed at $2.00 after 20 trading sessions, up 10.83% for the selected period.

Last close
$2.00
Period change
+10.83%
Period low
$1.80
Period high
$2.29
Daily close
View OHLC price history
CRDL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 11, 2026$2.03$2.0779$1.945$1.9951.24M
Sep 10, 2026$2.21$2.24$1.975$1.981.78M
Sep 9, 2026$2.22$2.34$2.21$2.2851.97M
Sep 8, 2026$2.20$2.24$2.16$2.221.24M
Sep 4, 2026$2.16$2.2191$2.12$2.201.1M
Sep 3, 2026$2.18$2.20$2.085$2.16976.67K
Sep 2, 2026$2.16$2.235$2.095$2.172.18M
Sep 1, 2026$1.94$2.19$1.93$2.152.12M
Aug 31, 2026$1.92$1.98$1.88$1.975780.88K
Aug 28, 2026$2.06$2.1129$1.90$1.941.66M
Aug 27, 2026$2.09$2.17$2.035$2.061.84M
Aug 26, 2026$2.03$2.275$2.01$2.144.53M
Aug 25, 2026$1.89$2.02$1.86$2.002.17M
Aug 24, 2026$1.88$1.88$1.7608$1.861.01M
Aug 21, 2026$1.93$1.9319$1.855$1.86753.35K
Aug 20, 2026$1.96$1.995$1.83$1.8851.53M
Aug 19, 2026$1.92$1.965$1.86$1.961.75M
Aug 18, 2026$1.82$1.90$1.735$1.8951.6M
Aug 17, 2026$1.73$1.94$1.73$1.802.33M
Aug 14, 2026$1.73$1.82$1.65$1.801.73M

Latest CRDL news

The latest Smart Investors Daily articles mentioning CRDL.

Stock researchCompany · Overview

CRDL research

Overview

Company profile and research snapshot.

Company profile

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$8.00
Implied upside
—
Analysts
—
CRDL recent ratings
DateFirmRatingTarget
Jul 12, 2026FIRST BERLIN EQUITY RESEARCHBuy—
May 11, 2026BROOKLINE CAPITAL MARKETSBuy—
Feb 25, 2026FIRST BERLIN EQUITY RESEARCHBuy—
Jan 21, 2026FIRST BERLIN EQUITY RESEARCHBuy—
Jan 20, 2026FIRST BERLIN EQUITY RESEARCHBuy—
Open full forecast

News briefing

Generated Sep 11, 2026, 9:13 PM

Why Is CRDL Up Today?

Cardiol Therapeutics (CRDL) is experiencing a modest gain of 0.76% today, driven by positive visibility from its upcoming participation in the H.C. Wainwright 28th Annual Global Investment Conference. This fireside chat engagement suggests the company is actively engaging with institutional investors and the investment community to discuss its strategic direction and pipeline progress.

    Bottom line: CRDL's modest daily gain reflects incremental positive sentiment from increased investor visibility through its H.C. Wainwright conference participation, though the market's muted reaction suggests limited immediate catalysts. Investors should monitor the actual fireside chat content and any announcements for meaningful developments in the company's cardiac therapeutic pipeline that could drive more substantial momentum.

    Yahoo · Sep 9, 2026

    Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY, on September 14, 2026, at 10:30 a.m. EDT.

    AI research layers

    Interpretive context generated from the platform’s current data sources.

    No results

    AI research layers have not been published yet.

    Featured By